RAPP

23.1801.74%
SM

Steven M. Paul

Member of Advisory Board

Dr. Steven M. Paul, M.D., also known as Steve, serves as Venture Partner at Third Rock Ventures, LLC, which he joined in September 2010. He is Founder of Rapport Therapeutics, Inc. and also serves as Independent Chairman since December 2022. He is Founder of Seaport Therapeutics, Inc. and also serves as Non-Employee Chair of the Board since April 2024. He serves as Chair of Foundation For The National Institutes Of Health Inc. since May 19, 2016. He is Co-Founder of Tal Medical, Inc., which he joined in 2010, and also serves as Director and SAB Chair. Dr. Paul serves as Director at ImClone Systems LLC since November 21, 2008. He serves as Director at Seaside Therapeutics, LLC since July 2010. He serves as Independent Director at EMD Millipore Corporation since November 2006. He serves on the board of directors of One Mind Institute since April 07, 2026. He also serves as Director at Allen Institute for Brain Science, Director at Syremis Therapeutics Ltd., Mentor & Advisor of One Mind Accelerator, Member of the Science Advisory Board of The Mind Research Network, Member of the Advisory Board of BioXcel Therapeutics, Inc., and Member of the Scientific Advisory Board of Retromer Therapeutics, Inc. His prior experience includes serving as a Board Member at Flare Therapeutics Inc. until 2025. He served as Independent Director at Sage Therapeutics, Inc. from September 2011 to June 11, 2024. He served at Karuna Therapeutics, Inc. until March 18, 2024; at the company, he served as Director and Member of the Scientific Advisory Board from January 16, 2024 to March 18, 2024, as President of Research and Development, Chief Scientific Officer & Director from January 3, 2023 to January 16, 2024, as CEO, President & Chairman until January 3, 2023, and as Chairman & CEO since August 15, 2018. He served at Voyager Therapeutics, Inc. until June 6, 2022, which he joined in June 2013; at the company, he served as Executive Science Advisor & Director from August 2018 to June 6, 2022, as CEO, President & Director on July 16, 2018, and as Director from June 17, 2018 to August 2018. He served as Independent Director at Alnylam Pharmaceuticals, Inc. from September 2010 to April 16, 2022. He served as Director at Constellation Pharmaceuticals, Inc., which he joined on February 1, 2011. He served at Eli Lilly and Company as Executive Vice President of Science & Technology and President of Lilly Research Laboratories from May 16, 2003 to February 28, 2010. Dr. Paul also served as Member of the Scientific Advisory Board of Avalo Therapeutics, Inc., Advisor of PureTech Health plc, Member of the Scientific Advisory Board of PsychoGenics, Inc., Director of DemeRx, Inc., Scientific Advisor of Excalibur Fund Managers Limited, and Director of BioCrossroads. Dr. Paul has a M.S. in Anatomy & Neuroanatomy and a M.D. from Tulane University School of Medicine in 1975, and a B.A. in Biology & Psychology from Tulane University in 1972.

Positions